A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed
multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms
tumor who have a specific chromosomal abnormality
do better with a more intensive, augmented chemotherapy regimen